Morcos S K, Oldroyd S, Haylor J
Department of Diagnostic Imaging, Northern General Hospital NHS Trust, Sheffield, UK.
Br J Radiol. 1997 Feb;70:154-9. doi: 10.1259/bjr.70.830.9135441.
The effect of diatrizoate (Urografin325) on the cumulative dose-response curve of the vasodilatory response to acetylcholine was studied in the isolated perfused rat kidney (IPRK). The effect of 1-nitroarginine methyl ester (L-NAME) (10 mumol l-1) on the cumulative concentration-response curve of the vasodilatory response to acetylcholine and sodium nitroprusside was also studied. Acetylcholine is a vasodilator dependent on nitric oxide (NO) synthesis by the endothelium; sodium nitroprusside is a vasodilator not dependent on endogenous NO synthesis and L-NAME is an inhibitor of endogenous NO synthesis. The effect of L-NAME (10 mumol l-1) on the vasodilatory effect of diatrizoate which is observed in the presence of endothelin A receptor antagonist (BQ123, 10 mumol l-1) was also studied. In all experiments an infusion of angiotensin II (5 ng min-1) was maintained to increase the vascular tone of the preparation. Acetylcholine induced vasodilatation and the maximum increase in renal perfusate flow (RPF) was 17.0 +/- 1.7%, (p < 0.05). Diatrizoate (20 mgl ml-1 perfusate concentration) which induced a sustained fall in the RPF (-31.0 +/- 1.7%, p < 0.05) had no effect on the vasodilatory response to acetylcholine, and a similar increase in the RPF (17.8 +/- 2.2%, p < 0.05) was observed. In contrast, L-NAME (10 mumol l-1) completely abolished the vasodilatory effect of acetylcholine and produced instead a modest decrease in RPF by -5.0 +/- 1.7% (p < 0.05). The vasodilatory effect of sodium nitroprusside was not affected by L-NAME, confirming its selectivity as an inhibitor of endogenous NO synthesis in the IPRK. The maximum increase in the RPF induced by sodium nitroprusside was 23.1 +/- 2.0% (p < 0.05) in the absence of L-NAME and 21.2 +/- 2.2% (p < 0.05) in its presence. L-NAME did not interfere with the vasodilatation induced by diatrizoate in the presence of BQ123. In the presence of BQ123 alone the RPF increased from 23.3 +/- 1.4 ml min-1 g-1 to 26.5 +/- 1.0 ml min-1 g-1 (p < 0.05). In the presence of L-NAME and BQ123 the RPF increased from 24.4 +/- 3.0 ml min-1 g-1 to 27.2 +/- 2.7 ml min-1 g-1 (p < 0.05). There was no difference between the two groups (p > 0.05). In conclusion, diatrizoate did not interfere with endothelium derived NO-dependent vasodilatation in the kidney. A reduced production of NO in the vascular endothelium induced by contrast media is unlikely to play any role in the pathophysiology of the increase in renal vascular resistance produced by these agents. The renal vasodilatation induced by diatrizoate is not dependent on endogenous production of NO.
在离体灌注大鼠肾脏(IPRK)中研究了泛影酸盐(优维显325)对乙酰胆碱血管舒张反应的累积剂量-反应曲线的影响。还研究了1-硝基精氨酸甲酯(L-NAME)(10 μmol/L)对乙酰胆碱和硝普钠血管舒张反应的累积浓度-反应曲线的影响。乙酰胆碱是一种依赖内皮细胞一氧化氮(NO)合成的血管舒张剂;硝普钠是一种不依赖内源性NO合成的血管舒张剂,而L-NAME是内源性NO合成的抑制剂。还研究了L-NAME(10 μmol/L)对在存在内皮素A受体拮抗剂(BQ123,10 μmol/L)时观察到的泛影酸盐血管舒张作用的影响。在所有实验中,维持血管紧张素II(5 ng/min)的输注以增加标本的血管张力。乙酰胆碱诱导血管舒张,肾灌注液流量(RPF)的最大增加为17.0±1.7%,(p<0.05)。泛影酸盐(灌注液浓度20 mg/ml)导致RPF持续下降(-31.0±1.7%,p<0.05),但对乙酰胆碱的血管舒张反应无影响,观察到RPF有类似的增加(17.8±2.2%,p<0.05)。相比之下,L-NAME(10 μmol/L)完全消除了乙酰胆碱的血管舒张作用,反而使RPF适度下降了-5.0±1.7%(p<0.05)。硝普钠的血管舒张作用不受L-NAME影响,证实了其作为IPRK中内源性NO合成抑制剂的选择性。在不存在L-NAME时,硝普钠诱导的RPF最大增加为23.1±2.0%(p<0.05),在存在L-NAME时为21.2±2.2%(p<0.05)。在存在BQ123的情况下,L-NAME不干扰泛影酸盐诱导的血管舒张。仅在存在BQ123时,RPF从23.3±1.4 ml·min-1·g-1增加到26.5±1.0 ml·min-1·g-1(p<0.05)。在存在L-NAME和BQ123时,RPF从24.4±3.0 ml·min-1·g-1增加到27.2±2.7 ml·min-1·g-1(p<0.05)。两组之间无差异(p>0.05)。总之,泛影酸盐不干扰肾脏中内皮源性NO依赖性血管舒张。造影剂诱导的血管内皮中NO产生减少不太可能在这些药物引起的肾血管阻力增加的病理生理学中起任何作用。泛影酸盐诱导的肾血管舒张不依赖于内源性NO的产生。